Latterell Venture Partners

Jim Woody

Jim brings more than 25 years of pharmaceutical research and management experience to LVP.  In addition to his duties at LVP, Jim is currently chairman of Oncomed Pharmaceuticals, where he previously served as the founding CEO and helped organize the formation of the company.  Jim was formerly President of Roche Bioscience in Palo Alto, CA. where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development of numerous new pharmaceuticals. Previously, Jim served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Jim developed Remicade, the first of the TNF inhibitor biologics, as well as ReoPro, a novel platelet blocking drug used in conjunction with angioplasty.

Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.

Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.

Copyright © 2014 by Latterell Venture Partners

LVP is Registered in the US Patent and Trademark Office